superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
- Valid from
- 2022-12-31
- Valid until
- 2023-12-31
- Published
- 2023-02-01
- Recorded by AsOf
- 2026-11-08
- Checked
- 2026-11-08 · parsed from the SEC filing
- Confidence
- 0.95
- Replaced by
- 232,261,000,000 DKK
Sources
Cite this claim
Plain text
AsOf. "Novo Nordisk revenue: 176,954,000,000 DKK", as of 2022-12-31 (until 2023-12-31). Claim clm_459BEEC0AB43, https://asof.is/claim/clm_459BEEC0AB43, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm.
APA
AsOf. (2022). Novo Nordisk revenue: 176,954,000,000 DKK (as of 2022-12-31 (until 2023-12-31)) [Record clm_459BEEC0AB43]. Retrieved November 9, 2026, from https://asof.is/claim/clm_459BEEC0AB43 (source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm)
BibTeX
@misc{asof_clm_459BEEC0AB43,
author = {AsOf},
title = {Novo Nordisk revenue: 176,954,000,000 DKK},
year = {2022},
howpublished = {\url{https://asof.is/claim/clm_459BEEC0AB43}},
note = {Claim clm\_459BEEC0AB43, as of 2022-12-31 (until 2023-12-31); source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm},
urldate = {2026-11-09}
}Supersedes
On the record
/claim/clm_459BEEC0AB43.md/v1/claims/clm_459BEEC0AB43submit a correction